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SHORT REPORT
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sclerosis supports shared pathogenesis
JOHN P. FRANKLIN1, JOHNATHAN COOPER-KNOCK1,
ARAVINDHAN BAHEERATHAN2, TOBIAS MOLL1, ROOPE MÄNNIKKÖ3,
MARK HEVERIN4, ORLA HARDIMAN4, PAMELA J. SHAW1 AND
MICHAEL G. HANNA2,3
1
Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK,
2
Department of
Neurology, University College London Hospitals NHS Foundation Trust, London, UK,
3
MRC Centre for
Neuromuscular Diseases, UCL Institute of Neurology, The National Hospital for Neurology and Neurosurgery,
London, UK, and
4
School of Medicine, Trinity College Dublin, Dublin, Ireland
Abstract
Amyotrophic lateral sclerosis (ALS) is an invariably fatal adult-onset neurodegenerative disorder; approximately 10% of
ALS is monogenic but all ALS exhibits significant heritability. The skeletal muscle sodium channelopathies are a group
of inherited, non-dystrophic ion channel disorders caused by heterozygous point mutations in the SCN4A gene, leading
to clinical manifestations of congenital myotonia, paramyotonia, and periodic paralysis syndromes. We provide clinical
and genetic evidence of concurrence of these two rare disorders which implies a possible shared underlying pathophysi-
ology in two patients. We then identify an enrichment of ALS-associated mutations in another sodium channel, SCN7A,
from whole genome sequencing data of 4495 ALS patients and 1925 controls passing multiple testing correction (67 var-
iants, p¼0.0002, Firth logistic regression). These findings suggest dysfunctional sodium channels may play a role
upstream in the pathogenesis of ALS in a subset of patients, potentially opening the door to novel personalized medi-
cine approaches.
Keywords: Genetics, excitotoxicity, risk
Case reports
We present a 72-year-old Caucasian gentleman
who developed ALS on a background of sodium
channel myotonia due to p.Ser1159Pro mutation
in SCN4A (Figure 1). This mutation co-segre-
gated with myotonia in the index pedigree (Figure
2) and it is absent from 141,456 control individu-
als within gnomAD (1). Within the SC4A protein
p.Ser1159Pro is located in the S4-S5 loop in close
proximity to previously described p.Ala1152Asp,
p.Ala1156Thr, and p.Ile1160Val mutations, and it
is predicted to be pathogenic in silico (2). The
patient reported lifelong mild cramping and myo-
tonia affecting his hands and eyelids. At age of 70,
he presented with progressive limb weakness ini-
tially most prominent in the left hand followed by
bulbar weakness. Clinical examination revealed
weakness and wasting in all limbs, increased
muscle tone, brisk tendon reflexes, and widespread
fasciculations. Tongue movements were slow and
spastic, and marked dysarthria was noted.
Electrophysiological studies revealed chronic
neurogenic changes on a background of wide-
spread fibrillation and fasciculation, but also sharp
waves and myotonia. A clinical diagnosis of ALS
was made. Lumbar puncture, MRI brain and spine
imaging, and blood investigations did not demon-
strate an alternative cause. He commenced
Riluzole, but deteriorated and died from respira-
tory infection 2 years after the onset of
ALS symptoms.
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We hypothesized that SCN4A mutation may
have predisposed our patient to develop ALS. We,
therefore, screened 1138 familial ALS patients
(als.umassmed.edu/) for additional pathogenic
mutations within SCN4A. While no further
patients carrying p.Ser1159Pro mutations were
identified, we identified a single Caucasian male
carrying a rare p.Arg672His mutation (ClinVar:
www.ncbi.nlm.nih.gov/clinvar/variation/VCV00000
5912.1, Figure 1) who developed dysarthria and
dysphagia aged 66 years. A diagnosis of familial
ALS was made 12 months later. No other muta-
tions in previously described ALS genes were iden-
tified. Despite Riluzole, he died from respiratory
failure 18 months after symptom onset.
p.Arg672His is typically associated with
hypokalemic periodic paralysis (hypoPP) type 2,
which may clinically overlap with sodium channel
myotonia (3). Available records were insufficient
to confirm clinical/electrophysiological evidence of
sodium channel dysfunction.
Discussion
We are the first to report clinical and genetic evi-
dence of SCN4A-channelopathy preceding devel-
opment of ALS. Observed concurrence may be
coincidence, but both conditions are rare (4) and,
therefore, a common pathway for pathogenesis
should be considered. Extensive observational evi-
dence has linked ALS to sodium channel dysfunc-
tion, but our genetic data tentatively places
Figure 1. Schematic representation of SCN4A mutations identified in ALS patients. Clinically reported neuromuscular phenotype
highlighted in boxes. Identified genetic changes within SCN4A are proposed to lead to motor neuron toxicity by one of two
mechanisms: either directly via excessive membrane sodium permeability leading to hyperexcitability and ultimately excitotoxicity; or
indirectly via muscle hyperexcitability leading to retrograde motor neuron toxicity.
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sodium channel dysfunction upstream in the devel-
opment of ALS in selected cases.
While the pathophysiology of ALS is not fully
elucidated, aberrant sodium conductance is impli-
cated in both sporadic and familial forms
(reviewed in (5)) with excitotoxicity considered
responsible for motor neuron death. NaV1.4
(encoded by SCN4A) is a voltage-gated sodium
channel expressed predominantly in muscle sarco-
lemma. Changes in muscle excitability have been
linked to retrograde motor neuron toxicity (6)
(Figure 1) but it is noticeable that SCN4A is
expressed within the CNS (7,8).
The two SCN4A mutations we have identified
are typically associated with opposite effects on
muscle excitability – hyperexcitability and sodium
channel myotonia (p.Ser1159Pro) versus hypoex-
citability and hypoPP type 2 (p.Arg672His) (3).
p.Arg672His enables an abnormal inward cation
“gating pore” current which depolarizes the cell
leading to inactivation of sodium channels and
hypoexcitability; however, similar mutations are
linked to paradoxical depolarization at low-normal
extracellular [Kþ] leading to hyperexcitability (9).
This explains the clinical overlap with sodium
channel myotonia (3). We hypothesize that
p.Arg672His-SCN4A would produce membrane
hyperexcitability in the CNS where extracellular
[Kþ] is lower (10). In both of our patients, we
speculate that abnormal NaV1.4 channels within
motor neuron membranes predisposed to depolar-
ization-induced cellular excitotoxicity, leading to
the development of ALS (Figure 1). Alternatively,
changes in muscle excitability have been linked to
retrograde motor neuron toxicity, and may have
played a role in the etiology of these cases (Figure
1) (6). Further mechanistic studies are required.
We hypothesized that ALS may be linked to
genetic mutations in other voltage-gated ion
channels. Rare-variant burden testing using whole
genome sequencing data from 4495 ALS patients
and 1925 controls (databrowser.projectmine.com/)
within the superfamily of voltage-gated ion chan-
nels (Accession:ssf81324) identified one gene,
SCN7A, which passed multiple testing correction
(p¼ 0.00029, beta ¼ 0.41, Firth logistic regression;
rare-variants defined as missense and MAF <
0.01, Supplementary Table) consistent with an
enrichment of ALS-associated mutations. SCN7A
encodes a type II sodium channel, NaX, and is
expressed in glial cells. NaX is not voltage-gated,
and channel permeability is proportional to extra-
cellular [Naþ] so as to mediate [Naþ] homeostasis
(11). We identified 67 rare predicted pathogenic
(12) ALS-associated variants within SCN7A of
which 3 are premature stop codon variants which
undoubtedly lead to haploinsufficiency
(Supplementary Table). We propose that SCN7A
loss of function may disrupt extracellular [Naþ]
homeostasis and lead to neuronal hyperexcitability.
Our findings add to the growing body of evi-
dence for sodium channel dysfunction in ALS.
Identification of upstream genetic mutations may
ultimately provide the basis for a personalized
medicine approach.
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Figure 2. Pedigree from index case. Pedigree showing co-segregation of SCN4A p.Ser1159Pro with congenital myotonia. (shaded:
congenital myotonia, crosshatch: ALS and congenital myotonia,  ¼ SCN4A p.Ser1159Pro mutation confirmed).
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